Vernalis PLC Regulatory News (VER)

28 Oct 2008 11:00



28th October 2008

Vernalis Announces Directorate Change

Vernalis plc (LSE: VER) announces today the forthcoming departure of Mr Tony Weir, Chief Financial Officer. He will be leaving on 14th November 2008 to join another company in the life sciences sector.

Commenting, Peter Fellner, Chairman said:

"On behalf of the Board I would like to thank Tony for his considerable contribution as a key member of the management team over the past years. We wish him every success in his future career".

The Company is in advanced discussions with potential successors, and expects to announce a new appointment shortly.

-- ends --

Enquiries:

Notes to Editors

About Vernalis

Vernalis is an R&D-based pharmaceutical company with one marketed product, Frova®, six products in clinical development, and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec, Endo, Menarini and Chiesi:

For further information about Vernalis, please visit www.vernalis.com.

Forward-Looking Statement

This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of Frova® and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.